

## Nanexa granted patent in the USA

**Nanexa AB (publ) today announced that the company has received a new patent in the USA. The newly issued patent (US 11,214,865 B2) relates to an ALD reactor adapted for large scale production of PharmaShell® coated drugs.**

"This patent, which has already been granted in the UK (GB 2576851 B), is a good complement to our product and process patents for the drug delivery system PharmaShell®," says David Westberg, CEO of Nanexa.

ALD (Atomic Layer Deposition) is the chemical process Nanexa uses to produce the drug delivery platform PharmaShell®.

### **For additional information, please contact:**

---

David Westberg – CEO, Nanexa AB (publ)

Phone: +46 70 942 83 03

Email: [david.westberg@nanexa.se](mailto:david.westberg@nanexa.se)

[www.nanexa.com](http://www.nanexa.com)

Erik Penser Bank is the company's Certified Adviser and can be reached on +46 8 463 83 00, email: [certifiedadviser@penser.se](mailto:certifiedadviser@penser.se)

### **About Nanexa AB (publ)**

---

Nanexa AB is a nanotechnology drug delivery company focusing on the development of PharmaShell®, a new and groundbreaking drug delivery system with great potential for a number of medical substance types and indications. Within the framework of PharmaShell®, Nanexa develops its own products and has collaboration agreements with several pharma companies, among others AstraZeneca.

Nanexa's share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA).

### **Attachments**

---

[Nanexa granted patent in the USA](#)